References
1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to
the World Health Organization classification of myeloid neoplasms and
acute leukemia. Blood 2016; 127 : 2391–405.
2. Julia F, Dalle S, Duru G, et al. Blastic plasmacytoid
dendritic cell neoplasms: Clinico-immunohistochemical correlations in a
series of 91 patients. Am J Surg Pathol 2014; 38 :
673–80.
3. Venugopal S, Zhou S, El Jamal SM, Lane AA, Mascarenhas J. Blastic
Plasmacytoid Dendritic Cell Neoplasm–Current Insights. Clin
Lymphoma, Myeloma Leuk 2019; 19 : 545–54.
4. Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid
dendritic cell neoplasm: Diagnostic criteria and therapeutical
approaches. Br J Haematol 2016; 174 : 188–202.
5. Martín-Martín L, López A, Vidriales B, et al. Classification
and clinical behavior of blastic plasmacytoid dendritic cell neoplasms
according to their maturation-associated immunophenotypic profile.Oncotarget 2015; 6 : 19204–16.
6. Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE
chemotherapy for newly diagnosed stage IV, relapsed, or refractory
extranodal Natural Killer (NK)/T-cell lymphoma, nasal type: The NK-cell
tumor study group study. J Clin Oncol 2011; 29 : 4410–6.
7. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic
Mutations of Calreticulin in Myeloproliferative Neoplasms. N Engl
J Med 2013; 25 : 2379–90.
8. Nakao K, Oka S, Utsumi T, et al. [Concurrent CALR and SF3B1
gene mutations in a patient with myelodysplastic/myeloproliferative
neoplasm with ring sideroblasts and thrombocytosis]. Rinsho
Ketsueki 2019; 60 : 915–9.
9. Taylor J, Haddadin M, Upadhyay VA, et al. Multicenter Analysis
of Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm Offers a
Pre-Targeted Therapy Benchmark. Blood 2019; 134 :
678–87.
10. Sakamoto K, Katayama R, Asaka R, et al. Recurrent 8q24
rearrangement in blastic plasmacytoid dendritic cell neoplasm:
association with immunoblastoid cytomorphology, MYC expression, and drug
response. Leukemia 2018; 32 : 2590–603.
11. Pagano L, Valentini CG, Pulsoni A, et al. Blastic
plasmacytoid dendritic cell neoplasm with leukemic presentation: An
italian multicenter study. Haematologica 2013; 98 :
239–46.
12. Suzuki R. NK/T-cell lymphomas: Pathobiology, prognosis and treatment
paradigm. Curr Oncol Rep 2012; 14 : 395–402.
13. Sugimoto KJ, Shimada A, Yamaguchi N, et al. Sustained
complete remission of a limited-stage blastic plasmacytoid dendritic
cell neoplasm followed by a simultaneous combination of low-dose DeVIC
therapy and radiation therapy: A case report and review of the
literature. Int J Clin Exp Pathol 2013; 6 : 2603–8.
14. Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the
evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in
adults and children with malignant diseases: An expert TLS panel
consensus. Br J Haematol 2010; 149 : 578–86.